Thermo Fisher Scientific (TMO) Receives New Coverage from Analysts at BTIG Research

Investment analysts at BTIG Research assumed coverage on shares of Thermo Fisher Scientific (NYSE:TMO) in a report released on Friday, MarketBeat reports. The firm set a “buy” rating and a $230.00 price target on the medical research company’s stock. BTIG Research’s price target would suggest a potential upside of 13.64% from the company’s previous close.

TMO has been the topic of a number of other reports. Jefferies Group reaffirmed a “hold” rating and set a $195.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price objective on the stock in a research report on Thursday, September 7th. Leerink Swann reiterated an “outperform” rating and issued a $200.00 price objective (down from $216.00) on shares of Thermo Fisher Scientific in a research report on Monday, December 4th. Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price objective on the stock. Finally, Evercore ISI began coverage on shares of Thermo Fisher Scientific in a research report on Wednesday. They issued an “outperform” rating and a $220.00 price objective on the stock. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $212.21.

Thermo Fisher Scientific (NYSE TMO) opened at $202.39 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. Thermo Fisher Scientific has a 12 month low of $140.00 and a 12 month high of $202.65. The firm has a market cap of $81,157.38, a price-to-earnings ratio of 22.24, a PEG ratio of 1.65 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $5.03 billion. During the same period in the prior year, the company posted $2.03 EPS. The business’s revenue for the quarter was up 13.9% on a year-over-year basis. research analysts predict that Thermo Fisher Scientific will post 9.36 earnings per share for the current year.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $191.74, for a total value of $9,587,000.00. Following the transaction, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.49% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in TMO. Bank of Nova Scotia Trust Co. purchased a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $106,000. Chicago Partners Investment Group LLC purchased a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $108,000. Shine Investment Advisory Services Inc. purchased a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $113,000. Ropes Wealth Advisors LLC lifted its holdings in Thermo Fisher Scientific by 15.8% in the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 97 shares in the last quarter. Finally, Atlantic Trust LLC purchased a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $138,000. Institutional investors own 86.22% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Market News and is the sole property of of American Market News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/07/thermo-fisher-scientific-tmo-receives-new-coverage-from-analysts-at-btig-research.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.